Kansas, Virginia, Maine, and North Carolina are considering expanding their Medicaid programs as a result of the GOP’s failure last week to begin the replacement of the ACA, the Wall Street Journal reports.  

The first treatment for the most severe form of multiple sclerosis—primary progressive MS—has been approved by the FDA.

The FDA has approved niraparib (Zejula, Tesaro, Inc.) for the maintenance treatment of adult women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer whose tumors have shown a complete or partial response to platinum-based chemotherapy.

A report from the National Academies of Sciences, Engineering, and Medicine proposes a strategy to eliminate hepatitis B and C as serious U.S. public health problems and prevent nearly 90,000 deaths by 2030.

Dupilumab injection (Dupixent, Regeneron/Sanofi) has received FDA approval as the first biologic medicine approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

The Mississippi delta is in the cross-hairs of the Zika virus, according to Saint Louis University researchers. Their study also predicts that the virus, which is spread sexually and by bites from the Aedes aegypti mosquito, is likely to be transmitted in southeastern states, northward along the Atlantic coast, and in southern California.

A variety of organizations combine different measurements to produce “report cards” showing how well hospitals serve their patients and keep them safe. Some use only objective patient outcomes, such as infection rates, while others allow hospitals to report on their efforts to improve safety.

The United States will not have nearly enough physicians to treat everybody who needs treatment in the coming years. By 2030, there will be a deficit of between 40,800 and 104,900 doctors, according to a report by the Association of American Medical Colleges (AAMC).

Several European organizations, led by Medecins du Monde and Doctors Without Borders, have challenged Gilead saying that the base compound for Sovaldi is not unique enough that it could preclude someone else from having already created it.

Philips Healthcare is recalling 47,362 HeartStart MRx Monitor/Defibrillators due to electrical and battery connection issues that may prevent the device from powering up, charging, and delivering an electrical shock therapy, according to the FDA. The device may also unexpectedly stop pacing.

Scientists have uncovered a treasure trove of information about the genetic causes of brain cancer in the largest-ever study of the disease. A group of international researchers has revealed 13 new genetic errors associated with an increased risk of developing glioma—the most common form of brain cancer.

Sovaldi (sofosbuvir) cures 90% of hepatitis C virus (HCV) infections, bringing hope for millions of patients infected with the dangerous liver disease. But critics say the manufacturer, Gilead Sciences, has priced it out of the reach of many patients and public health systems. A single Sovaldi pill can cost up to $1,000.

Two pivotal phase 3 trials of sarecycline (Allergan/Paratek) for the treatment of moderate-to-severe acne have met their 12-week primary endpoints of efficacy and safety.

In a new perspective article led by Sancy Leachman, MD, PhD, and Mariah Johnson, MD, from the Oregon Health & Science University (OHSU) Knight Cancer Institute’s Melanoma Research Program at the OHSU School of Medicine, more than 50 leading members of the skin cancer field combined their expertise to review screening practice in primary care, as recommend

The FDA has approved avelumab injection (intravenous) 20 mg/mL (Bavencio, EMD Serono) for the treatment of adults and pediatric patients 12 years of age and older with metastatic Merkel cell carcinoma (mMCC).

Pages